A table showing the expiration dates for the main U.S. and EU patents on the 50 top pharmaceutical products by 2024 sales.
*semaglutide is sold as Ozempic and Rybelsus for diabetes and Wegovy for obesity, while tirzepatide is sold as Mounjaro for diabetes and Zepbound for obesity. Denosumab is sold as Prolia for osteoporosis and Xgeva for other bone conditions.
Tafamidis is sold as Vyndamax or Vyndamac, depending on market. Settlements will delay generic entry in the U.S. until 2031.
#Legal settlements to delay entry of Rinvoq generics until 2037 (with pediatric exclusivity to 2038). Legal settlement to delay entry of Eliquis generics until 2028. Settlement delayed entry of Stelara biosimilars until 2025. Settlement to delay entry of generic Xarelto until 2027. Humira biosimilars arrived in the U.S. in 2023.
^Darzalex Faspro subcutaneous is covered by other patents not listed here. U.S. and Europe patents for Eylea HD expire in 2039 and 2042, respectively. Prevnar 13 patents expire in the U.S. in 2026; Other listed patent expirations are for Prevnar 20. Formulation and additional patents for Orencia expire in 2026 and beyond.
&Keytruda sales numbers include Keytruda Qlex. Keytruda Qlex patent expires in 2043. Opdivo sales numbers include Opdivo and Opdivo Qvantig.
@Roche does not disclose Hemibra or Ocrevus' expected loss of patent exclusivity. 2029 date is an estimate from Leerink Partners, and 2023 date is an estimate from Grand View Research. Tecentriq patent expiry is for the IV version.
#Legal settlements to delay entry of Rinvoq generics until 2037 (with pediatric exclusivity to 2038). Legal settlement to delay entry of Eliquis generics until 2028. Settlement delayed entry of Stelara biosimilars until 2025. Settlement to delay entry of generic Xarelto until 2027. Humira biosimilars arrived in the U.S. in 2023.
^Darzalex Faspro subcutaneous is covered by other patents not listed here. U.S. and Europe patents for Eylea HD expire in 2039 and 2042, respectively. Prevnar 13 patents expire in the U.S. in 2026; Other listed patent expirations are for Prevnar 20. Formulation and additional patents for Orencia expire in 2026 and beyond.
&Keytruda sales numbers include Keytruda Qlex. Keytruda Qlex patent expires in 2043. Opdivo sales numbers include Opdivo and Opdivo Qvantig.
@Roche does not disclose Hemibra or Ocrevus' expected loss of patent exclusivity. 2029 date is an estimate from Leerink Partners, and 2023 date is an estimate from Grand View Research. Tecentriq patent expiry is for the IV version.
Chart: Ben Fidler and Jonathan Gardner / BioPharma Dive